Tuberculosis Chemotherapy with Hydrazine Derivatives of Isonicotinic Acid

      • 1)
        Ninety-two patients with moderately or far-advanced pulmonary tuberculosis classified largely as progressive and caseous-pneumonic, have been treated with the hydrazide of isonicotinic acid (Rimifon) and its isopropyl derivative (Marsilid).
      • 2)
        All patients had positive sputum and active disease before institution of therapy. Forty-five were toxic and febrile.
      • 3)
        Patients, divided into groups, were treated with 2, 4, and 10 milligrams per Kilo of Marsilid and 4 mg. of Rimifon for from four to 15 weeks.
      • 4)
        Complete elimination of fever and toxicity occurred within two to three weeks in all cases. Appetite increase and restored sense of well-being were matched and overshadowed by weight gains which varied up to 64 pounds and averaged 18 pounds at an average of nine weeks of treatment.
      • 5)
        Sputum negativity was obtained in 25 per cent of patients in from four to 15 weeks of treatment and in another 28 per cent, sharp reductions from consistent plain smear positivity to “occasionally positive” occurred.
      • 6)
        Cough and expectoration were completely eliminated, or almost so, in from two to three weeks.
      • 7)
        Among the 92 cases, in from four to 15 weeks, cavity closure occurred in two cases, marked reduction in cavity size was noted in 33 cases, clearing of exudate occurred 17 times.
      • 8)
        Marked simultaneous diminution in several cavities within the same lung was seen three times.
      • 9)
        Extension of exudate occurred four times and was minimal. One equivical new cavity appeared at the site of a pre-therapy exudate.
      • 10)
        There was no death due to progression of tuberculosis.
      • 11)
        Cure or marked improvement has been seen in cases of tuberculous laryngitis, tuberculous otitis, tuberculous glossitis.
      • 12)
        Toxic effects of Marsilid and Rimifon therapy include hyper-reflexia, leg-twitching, constipation, vertigo and reflex disturbance of micturition.
      • 13)
        No death due to therapy has occurred.
      • 14)
        Every patient has been benefited by therapy.
      • 15)
        Clinical investigation of these previously untried new compounds, the hydrazide of isonicotinic acid (Rimifon) and its isopropyl derivative (Marsilid) reveals that they are potent agents for the treatment of human tuberculosis.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Fox H.H.
        “Synthetic Tuberculostats: III. Isonicotinaldehyde Thiosemicarbazone and Some Related Compounds,”.
        XIIth International Congress of Pure and Applied Chemistry, Sept. 9–13. Abstract of Papers, 1951: 299Chem. and Eng. News, Sept. 24. 1951; : 3964
        • Grunberg E.
        • Schnitzer R.J.
        “Studies on the Activity of Hydrazine Derivatives of Isonicotinic Acid in the Experimental Tuberculosis of Mice,”.
        Quart. Bull., Sea View Hosp. 1952; 13: 3
        • Orunberg E.
        • Leiwant B.
        • D'Ascensio I.L.
        • Schnitzer R.J.
        “On the Lasting Protective Effect of Hydrazine Derivatives of Isonicotinic Acid in the Experimental Tuberculosis Infection of Mice,”.
        Dis. of Chest. 1952; 21: 369
        • Zieper I.
        • Lewis R.A.
        “Tuberculosis in a Macacus Rhesus Treated with Isonicotinylhydrazine,”.
        Quart. Bull., Sea View Hosp. 1952; 13: 12
      1. Benson, W. M., Stefko, P. L. and Roe, M. D.: “Pharmacological and Toxicological Observations of Hydrazine Derivatives of Isonicotinic Acid,” Am. Rev. Tuberc., In press.

        • Lewis R.A.
        • Zieper I.
        “Tolerance of Macacus Rhesus for Isonicotinylhydrazine,”.
        Dis. of Chest. 1952; 21: 378
        • Selikoff I.J.
        • Robitzek E.H.
        • Ornstein G.G.
        “Toxicity of Hydrazine Derivatives of Isonicotinic Acid in the Chemotherapy of Human Tuberculosis,”.
        Quart. Bull., Sea View Hosp. 1952; 13: 17
        • Robitzek E.H.
        • Selikoff I.J.
        • Ornstein G.G.
        “Chemotherapy of Human Tuberculosis with Hydrazine Derivatives of Isonicotinic Acid,”.
        Quart. Bull., Sea View Hosp. 1952; 13: 27
        • Ornstein G.G.
        • Ulmar D.
        • Dittler E.C.
        “A Clinical Classification of Pulmonary Tuberculosis,”.
        Am. Rev. Tuberc. 1931; 23: 248
        • Rubin S.H.
        • Drekter L.
        • Scheiner J.
        • De Ritter E.
        “Determination of Blood Plasma Levels of Hydrazine Derivatives of Isonicotinic Acid,”.
        Dis. of Chest. 1952; 21: 439
      2. Robitzek, E. H. and Selikoff, I. J.: “Hydrazine Derivatives of Isonicotinic Acid in the Treatment of Active Progressive Caseous-pneumonic Tuberculosis,” Am. Rev. Tuberc., In press.

        • Severinghaus E.L.
        • Cohen S.
        • Gans R.H.
        • Lee S.N.
        “Nicotinamide Therapy of Lingual Changes in Tuberculous Patients,”.
        Am. Rev. Tuberc. 1950; 62: 360
        • Tchertkoff I.G.
        • Green H.
        “The Importance of Fever as a Diagnostic Sign of Intestinal Involvement in Chronic Pulmonary Tuberculosis,”.
        Quart. Bull., Sea View Hosp. 1942; 7: 231
        • Selikoff I.J.
        “Diagnosis of Generalized Amyloidosis by the Congo Red Test: Definitive Diagnostic Criteria,”.
        Am. J. Med. Sc. 1947; 213: 719
      3. Gold, G.: Personal communication.

        • Bosworth B.M.
        • Wright H.A.
        • Fielding J.W.
        “Marsalid in the Treatment of Tuberculosis Orthopedic Lesions,”.
        Quart. Bull., Sea View Hosp. 1952; 13: 52